Moreover, the APP expression level in the treatment group significantly decreased compared with that in the model group (p < 0.05); the expression of GSK3β in the treatment group had a downward trend, but it was not statistically significant, which indicated that Formula 9002A could effectively reduce the accumulation of APP and GSK3β and delay the development of AD. The gene discussed is APP; the disease is Alzheimer disease.